Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.
We report the case of a patient with stage 2 malignant melanoma (MM), who received a specific immunotherapy consisting of intralymphatic injections of irradiated MM cells. She developed subsequently vitiligo-like leukoderma and several plaques of localized scleroderma. Simultaneously an increase in the patient's cytotoxic activity against MM cells was detected in vitro. The responsibility of immune phenomena and specific immunotherapy for the appearance of depigmentation and morpheas is discussed.
Lacour
J P
JP
Department of Dermatology, Hôpital Pasteur, Nice, France.
Caldani
C
C
Thyss
A
A
Schneider
M
M
Ortonne
J P
JP
D000368:Aged; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D007272:Injections, Intralymphatic; D008207:Lymphatic Metastasis; D008545:Melanoma / Q000628:therapy*; D012594:Scleroderma, Localized / Q000209:etiology*; D012878:Skin Neoplasms / Q000628:therapy*; D014820:Vitiligo / Q000209:etiology*